Docs comfy with ePromotion, and many prefer it, says study

Share this article:
Sixty-seven percent of physicians had a positive attitude toward electronic promotional activities, up from 62% a year ago, according to an SDI study.

Additionally, 73% of the physicians surveyed for SDI's ePromotion Annual Study 2008 said pharma's electronic promotional activities (or ePromotion) were equal or superior to traditional face-to-face encounters.

“Through ePromotion, physicians have more time to review product information and review disease state information at their own convenience – at night time or on the weekends,” said Heather Alba, senior manager, promotional audits at SDI.

Other findings from the report include:
  • Sixty-nine percent of the physicians surveyed participated in ePromotional activities in the evening, outside of office hours. 
  • In 2008, the average amount of time spent by a physician on a single ePromotion activity was 18 minutes. 
  • Physicians ranked Merck as the leader in terms of the best ePromotion activities, followed by Pfizer and AstraZeneca respectively. 
The study, which included feedback from approximately 1,000 physicians across 14 specialties, defined ePromotion in three categories: virtual details (promotions without live communication); video details (live online promotion or telephone-assisted internet browsing); and virtual events (seminars, CME and KOL events, web conferences and group discussions).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...